4.5 Article

American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

Journal

ARTHRITIS & RHEUMATOLOGY
Volume 68, Issue 2, Pages 282-298

Publisher

WILEY
DOI: 10.1002/art.39298

Keywords

-

Categories

Funding

  1. Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH
  2. Abbott
  3. Amgen
  4. Pfizer
  5. Novartis
  6. AbbVie
  7. UCB
  8. Johnson Johnson
  9. Celgene
  10. Iroko
  11. Janssen
  12. Amgen/Pfizer
  13. GlaxoSmithKline
  14. Janssen/Johnson & Johnson/Centocor/Ortho Biotech Products
  15. Janssen Biotech
  16. Augurex
  17. Bristol-Myers Squibb
  18. Medtronic
  19. Ethicon
  20. Q-Med AB
  21. Centocor
  22. IDEC
  23. Xoma
  24. Roche
  25. Isis
  26. Pharmacia
  27. La Jolla Pharma
  28. Genentech
  29. Proctor Gamble
  30. Genelabs
  31. MedImmune
  32. Human Genome Sciences
  33. Array Biopharma
  34. Cipher
  35. Regeneron
  36. Lux Biosciences
  37. Elan
  38. Allergan
  39. Santen
  40. Teva
  41. Sanofi
  42. Janssen/Johnson Johnson

Ask authors/readers for more resources

Objective. To provide evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). Methods. A core group led the development of the recommendations, starting with the treatment questions. A literature review group conducted systematic literature reviews of studies that addressed 57 specific treatment questions, based on searches conducted in OVID Medline (1946-2014), PubMed (1966-2014), and the Cochrane Library. We assessed the quality of evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method. A separate voting group reviewed the evidence and voted on recommendations for each question using the GRADE framework. Results. In patients with active AS, the strong recommendations included use of nonsteroidal antiinflammatory drugs (NSAIDs), use of tumor necrosis factor inhibitors (TNFi) when activity persists despite NSAID treatment, not to use systemic glucocorticoids, use of physical therapy, and use of hip arthroplasty for patients with advanced hip arthritis. Among the conditional recommendations was that no particular TNFi was preferred except in patients with concomitant inflammatory bowel disease or recurrent iritis, in whom TNFi monoclonal antibodies should be used. In patients with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with TNFi. Other recommendations for patients with nonradiographic axial SpA were based on indirect evidence and were the same as for patients with AS. Conclusion. These recommendations provide guidance for the management of common clinical questions in AS and nonradiographic axial SpA. Additional research on optimal medication management over time, disease monitoring, and preventive care is needed to help establish best practices in these areas.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available